In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?  

If so, would you combine them vs monotherapy? Patient ECOG is 1



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Siri Onclogy and hematology Infusion Service
This patient should be on a clinical trial. In ref...
Sign in or Register to read more